Convelo Therapeutics specializes in developing medicines to regenerate myelin around nerve cells and restore function
Convelo Therapeutics has raised $10.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2022.
Convelo Therapeutics's investors include Zanite Ventures.
Convelo Therapeutics is headquartered in Cleveland, United States.
Convelo Therapeutics specializes in developing medicines to regenerate myelin around nerve cells and restore function
Convelo Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Convelo Therapeutics — Funding & Investors." VCBacked, December 8, 2022, https://www.vcbacked.co/company/convelo-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Convelo Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/convelo-therapeutics
{{cite web |title=Convelo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/convelo-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated